Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04248595Phase 2Unknown

Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

Role: lead

NCT05330364Phase 2Unknown

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Role: lead

NCT04062877Completed

Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma

Role: lead

NCT04490707Phase 3Unknown

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Role: lead

All 4 trials loaded